Shire on a roll as U.S. approves keenly awaited eye drug
Shire has won U.S. approval for its most important new medicine, a treatment for dry eyes, in a fresh boost for the company which completed its $32 billion acquisition of U.S. rare diseases specialist Baxalta last month. The Dublin-based drugmaker has been a big stock market winner following Britain's decision to leave the European Union, benefiting from the strength of the dollar against sterling and investor demand for defensive sectors like pharmaceuticals. Shire shares — already up a fifth since the UK referendum on June 23 — gained another 4 percent on Tuesday on news the U.S. Food and Drug Administration had approved lifitegrast eye drops for treating signs and symptoms of dry eye disease.